Table 1.
Baseline demographics of participants, dosage schedules and bone mineral density (BMD) values are provided for this Metaanalysis of Spinal BMD Changes per Year on Estrogen Therapy (ET) compared with Estrogen-Progestin Therapy (EPT) in trials that directly randomized women to one or the other group.
| Study Group | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| +PEPI | Liu | Adachi MPA: 10 | Adachi MPA: 20 | Lindsay CEE: 0.3 | Lindsay CEE: 0.45 | Lindsay CEE: 0.625 | Mizunuma | ||
| Number of Participants | ET* | 168 | 23 | 34 | 34 | 87 | 91 | 84 | 14 |
| EPT^ | 169 | 21 | 33 | 31 | 91 | 87 | 81 | 10 | |
| Age (years) | ET | 56.2 (3.9) | 52.0 (3.8) | 53.5 (7.4) | 53.5 (7.4) | 52.2 (3.9) | 51.9 (3.6) | 52.1 (3.1) | 55.1 (1.2) |
| EPT | 56.4 (3.9) | 52.9 (3.9) | 55.0 (6.8) | 53.6 (7.7) | 51.4 (3.5) | 51.6 (3.9) | 51.5 (4.2) | 53.7 (1.1) | |
| Ethnicity (% Caucasian) | ET | 91 | - | - | - | 90 | 89 | 92 | 0 (100% Asian) |
| EPT | 89 | - | - | - | 88 | 98 | 90 | 0 (100% Asian) | |
| Years Into Menopause (≥1 y with no flow) | ET | - | < 5 | 12.8 (8.8) | 12.8 (8.8) | 2.3 (1.0) | 2.5 (1.0) | 2.3 (0.9) | 5.1 - |
| EPT | - | < 5 | 12.8 (11.1) | 12.7 (9.4) | 2.3 (1.0) | 2.5 (0.9) | 2.2 (0.9) | 3.0 - | |
| Dosage (mg unless noted) | ET | 0.625 CEE | 1 mg 17β E2 | 0.625 CEE | 0.625 CEE | 0.3 CEE | 0.45 CEE | 0.625 CEE | 0.625 CEE |
| EPT | 0.625 CEE 2.5 MPA daily | 1 µg 17β E2 10 MPA daily | 0.625 CEE 10 MPA: 15 d/mo. | 0.625 CEE 20 MPA: 15 d/mo. | 0.3 CEE 1.5 MPA daily | 0.45 CEE 2.5 MPA daily | 0.625 CEE 2.5 MPA daily | 0.625 CEE 2.5 MPA daily | |
| Spine BMD at Baseline (g/cm2) | ET | 0.966 (0.146) | 1.140 (0.101) | 1.040 (0.135) | 1.040 (0.135) | 1.140 (0.150) | 1.135 (0.155) | 1.174 (0.153) | 0.842 (0.101) |
| EPT | 0.972 (0.171) | 1.132 (0.146) | 1.047 (0.160) | 1.067 (0.154) | 1.139 (0.145) | 1.152 (0.171) | 1.144 (0.164) | 0.830 (0.107) | |
| Total Hip BMD at Baseline (g/cm2) | ET | 0.860 (0.119) | - | - | - | 0.942 (0.121) | 0.954 (0.136) | 0.979 (0.136) | - |
| EPT | 0.854 (0.13) | - | - | - | 0.944 (0.122) | 0.956 (0.147) | 0.965 (0.144) | - | |
| Femoral Neck BMD at baseline (g/cm2) | ET | - | 0.866 (0.020) | 0.771 (0.121) | 0.771 (0.121) | - | - | - | 0.679 (0.099) |
| EPT | - | 0.873 (0.027) | 0.769 (0.118) | 0.786 (0.114) | - | - | - | 0.661 (0.084) | |
+These are intent-to-treat data from the Postmenopausal Estrogen Progestin Investigation (PEPI);
*
ET=estrogen alone therapy; EPT= estrogen with progesterone or osteoblast progesterone receptor-acting progestin; BMD=areal bone mineral density; CEE=conjugated equine estrogen; MPA=medroxyprogesterone acetate; mo. = month.